US FDA Approves Novo Nordisk's Diabetes Drug to Reduce Risk of Worsening Kidney Disease
(Reuters) - Novo Nordisk said on Tuesday the U.S. FDA has approved its diabetes drug Ozempic to reduce the risk of worsening kidney disease and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease.
The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...
A Novo Nordisk A/S investor says the pharmaceutical company’s failure to disclose how it tested experimental obesity shot ...
Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...
A multi-million dollar Super Bowl ad from telehealth company Hims and Hers downplays risks and side effects of compounded ...
Immvention Therapeutix is partnering with Novo Nordisk to develop oral treatments for sickle cell disease (SCD) and other ...
Moderna and Novo Nordisk are once again in the bad books of the U.K.’s drug marketing watchdog. | Moderna and Novo Nordisk ...
Here are some of the major companies whose stocks moved on the week’s news.
Minnesota announced a third and final settlement Monday in its price-fixing lawsuit against the so-called Big Three ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback